RxDoctor Payments Data

Whitney Dhyne, PA

Medical · Austin, TXNPI 1043642705

Payments from drug & device makers

$6,206in general payments, 2019–2025

Across 64 payments — averaging $96.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Autolus Inc$4K
  • Astellas Pharma US Inc$356
  • Novartis$321
  • Janssen Scientific Affairs, LLC$204
  • Legend Biotech USA Inc.$183
  • Johnson & Johnson$181
  • plus $754 from 7 others

What the payments were for

  • Speaking & faculty fees$2,77545%
  • Travel & lodging$1,17119%
  • Food & beverage$2,10034%
  • Education$1603%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,206 in reported general payments places this provider in the 85th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$3,697
Medicare patients
28
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OjjaaraMomelotinib Dihydrochloride19$525,816
JakafiRuxolitinib Phosphate27$428,676
EliquisApixaban21$12,311
ValacyclovirValacyclovir Hcl104$3,876
Fluconazole46$2,331
Ondansetron OdtOndansetron25$563
Famotidine30$255
Levofloxacin23$229
Prochlorperazine Maleate24$215
Azithromycin13$193
Potassium Chloride12$172
Allopurinol22$146
Carvedilol16$127
Gabapentin14$115
Amlodipine Besylate28$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKOjjaara$94$525,81619 claims
Incyte CorporationJakafi$125$428,67627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,490 medical providers in Texas.

Other medical in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →